AR066348A1 - Inhibidores de las iap - Google Patents
Inhibidores de las iapInfo
- Publication number
- AR066348A1 AR066348A1 ARP080101812A ARP080101812A AR066348A1 AR 066348 A1 AR066348 A1 AR 066348A1 AR P080101812 A ARP080101812 A AR P080101812A AR P080101812 A ARP080101812 A AR P080101812A AR 066348 A1 AR066348 A1 AR 066348A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycle
- optionally substituted
- carbocycle
- halogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 24
- 125000000623 heterocyclic group Chemical group 0.000 abstract 18
- -1 thiono Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 125000002252 acyl group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91501007P | 2007-04-30 | 2007-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066348A1 true AR066348A1 (es) | 2009-08-12 |
Family
ID=39926122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101812A AR066348A1 (es) | 2007-04-30 | 2008-04-29 | Inhibidores de las iap |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8907092B2 (enExample) |
| EP (1) | EP2148858A4 (enExample) |
| JP (1) | JP5368428B2 (enExample) |
| KR (1) | KR20100024923A (enExample) |
| CN (1) | CN101687787A (enExample) |
| AR (1) | AR066348A1 (enExample) |
| AU (1) | AU2008245447C1 (enExample) |
| BR (1) | BRPI0809867A2 (enExample) |
| CA (1) | CA2683392A1 (enExample) |
| CL (1) | CL2008001234A1 (enExample) |
| IL (1) | IL201379A0 (enExample) |
| MX (1) | MX2009011783A (enExample) |
| NZ (2) | NZ598890A (enExample) |
| PE (2) | PE20090211A1 (enExample) |
| RU (1) | RU2491276C2 (enExample) |
| TW (1) | TWI432212B (enExample) |
| WO (1) | WO2008134679A1 (enExample) |
| ZA (1) | ZA200906946B (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006020060A2 (en) | 2004-07-15 | 2006-02-23 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
| KR20120127754A (ko) | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| RU2418807C2 (ru) | 2005-10-25 | 2011-05-20 | Аегера Терапьютикс Инк. | Соединения, связывающие bir домены iap |
| TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| CL2007002167A1 (es) | 2006-07-24 | 2009-01-23 | Tetralogic Pharm Corp | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. |
| JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| PL2240506T3 (pl) * | 2008-01-11 | 2013-05-31 | Genentech Inc | Inhibitory IAP |
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| CA2730448A1 (en) | 2008-08-02 | 2010-02-11 | Genentech, Inc. | Inhibitors of iap |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CA2763638A1 (en) * | 2009-05-28 | 2010-12-02 | Tetralogic Pharmaceuticals Corp. | Iap inhibitors |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| SG181797A1 (en) | 2009-12-18 | 2012-07-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| MX340870B (es) | 2010-02-12 | 2016-07-27 | Pharmascience Inc | Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus. |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| EP2603216A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA34797B1 (fr) | 2010-08-11 | 2014-01-02 | Millennium Pharm Inc | Hétéroaryles et leurs utilisations |
| WO2012051410A2 (en) | 2010-10-13 | 2012-04-19 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| NO2755614T3 (enExample) * | 2012-01-03 | 2018-03-31 | ||
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| BR112014027413A2 (pt) | 2012-05-04 | 2017-06-27 | Novartis Ag | biomarcadores para terapia com inibidor de iap |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| BR112015021134A2 (pt) | 2013-03-15 | 2017-10-10 | Novartis Ag | conjugados de fármaco e anticorpo |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3151920B1 (en) | 2014-06-04 | 2025-08-06 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| PE20170903A1 (es) | 2014-08-12 | 2017-07-12 | Novartis Ag | Conjugados de farmacos con anticuerpos anti-cdh6 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2016203432A1 (en) | 2015-06-17 | 2016-12-22 | Novartis Ag | Antibody drug conjugates |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| SG11201802769RA (en) | 2015-10-29 | 2018-05-30 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| EP3592868B1 (en) | 2017-03-06 | 2022-11-23 | Novartis AG | Methods of treatment of cancer with reduced ubb expression |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN110662762A (zh) | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | 抗体细胞因子移植蛋白和用于治疗癌症的方法 |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| JP2020520671A (ja) | 2017-05-24 | 2020-07-16 | ノバルティス アーゲー | 抗体−サイトカイングラフト化タンパク質及び使用方法 |
| JP7210483B2 (ja) | 2017-06-30 | 2023-01-23 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規アザキノリン誘導体 |
| CN109836416B (zh) * | 2017-11-27 | 2023-02-03 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
| WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CU20210002A7 (es) | 2018-07-10 | 2021-08-06 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| PH12021551479A1 (en) | 2018-12-21 | 2022-07-18 | Novartis Ag | Antibodies to pmel17 and conjugates thereof |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| JP2022531436A (ja) * | 2019-07-25 | 2022-07-06 | ランザテク，インコーポレイテッド | 二次アセテート発酵 |
| WO2021023698A1 (en) | 2019-08-02 | 2021-02-11 | Lanthiopep B.V | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
| ES3061133T3 (en) | 2019-08-26 | 2026-03-31 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
| EP4093394A1 (en) | 2020-01-20 | 2022-11-30 | Astrazeneca AB | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022221720A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN120302969A (zh) * | 2022-09-29 | 2025-07-11 | 特拉克特制药公司 | 可用作iap抑制剂的化合物和组合物 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
| DE2714880A1 (de) | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE3685626T2 (de) | 1985-09-26 | 1993-01-28 | Beckmann Research Inst Of The | Sequenzierung von peptiden. |
| US4935494A (en) | 1988-11-15 | 1990-06-19 | City Of Hope | C-terminal peptide and protein sequencing |
| CA2012306A1 (en) | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
| DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| WO1992001938A1 (en) | 1990-07-20 | 1992-02-06 | City Of Hope | Derivatization of c-terminal proline |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5559209A (en) | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| CZ132798A3 (cs) | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
| AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6472172B1 (en) | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
| JP2002533726A (ja) | 1998-12-28 | 2002-10-08 | サネシス ファーマシューティカルス インコーポレイテッド | 結合のための小有機分子リガンドの同定 |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| AU2001286730A1 (en) | 2000-08-24 | 2002-03-04 | Thomas Jefferson University | An iap binding peptide or polypeptide and methods of using the same |
| US6992063B2 (en) | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| AU2001293189A1 (en) | 2000-09-29 | 2002-04-08 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
| US7718600B2 (en) | 2000-09-29 | 2010-05-18 | The Trustees Of Princeton University | IAP binding compounds |
| WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| WO2003010184A2 (en) | 2001-02-08 | 2003-02-06 | Thomas Jefferson University | A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis |
| KR100785109B1 (ko) | 2001-04-05 | 2007-12-12 | 토렌트 파마슈티칼스 리미티드 | 노화 관련 및 당뇨병 혈관성 합병증에 사용되는 헤테로사이클릭 화합물 |
| JP2004531731A (ja) | 2001-05-31 | 2004-10-14 | ザ トラスティーズ オブ プリンストン ユニバーシテイ | Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ |
| US20030157522A1 (en) | 2001-11-09 | 2003-08-21 | Alain Boudreault | Methods and reagents for peptide-BIR interaction screens |
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| CN100384819C (zh) | 2002-07-02 | 2008-04-30 | 诺瓦提斯公司 | 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂 |
| WO2004017991A1 (en) | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
| JP4315249B2 (ja) | 2003-02-07 | 2009-08-19 | ジェネンテック・インコーポレーテッド | アポトーシス亢進のための組成物と方法 |
| US20040171554A1 (en) | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| IL156263A0 (en) | 2003-06-02 | 2004-01-04 | Hadasit Med Res Service | Livin-derived peptides, compositions and uses thereof |
| US7067274B2 (en) | 2003-11-13 | 2006-06-27 | Genentech, Inc. | Compositions and methods for the screening pro-apoptotic compounds |
| MXPA06008095A (es) | 2004-01-16 | 2007-03-28 | Univ Michigan | Mimeticos de smac conformacionalmente restringidos y sus usos. |
| CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| AU2005218555B2 (en) | 2004-03-01 | 2008-01-03 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| CA2558615C (en) | 2004-03-23 | 2013-10-29 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| CA2570321C (en) | 2004-07-02 | 2013-10-08 | Genentech, Inc. | Inhibitors of iap |
| BRPI0513310A (pt) | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
| WO2006020060A2 (en) | 2004-07-15 | 2006-02-23 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
| KR20120127754A (ko) * | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| DK1851200T3 (da) * | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| RU2418807C2 (ru) * | 2005-10-25 | 2011-05-20 | Аегера Терапьютикс Инк. | Соединения, связывающие bir домены iap |
| RU2451025C2 (ru) | 2005-12-19 | 2012-05-20 | Дженентек, Инк. | Ингибиторы iap |
| TWI543988B (zh) * | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| EP1996184A4 (en) | 2006-03-21 | 2010-09-22 | Joyant Pharmaceuticals Inc | SMALL MOLECULAR APOPTOSIS PROMOTERS |
| WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110218A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044209B2 (en) | 2006-10-12 | 2011-10-25 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
| RU2466131C2 (ru) | 2006-12-19 | 2012-11-10 | Дженентек, Инк. | Имидазопиридиновые ингибиторы iap |
| PL2240506T3 (pl) | 2008-01-11 | 2013-05-31 | Genentech Inc | Inhibitory IAP |
| CA2730448A1 (en) | 2008-08-02 | 2010-02-11 | Genentech, Inc. | Inhibitors of iap |
| JP2012500272A (ja) | 2008-08-16 | 2012-01-05 | ジェネンテック， インコーポレイテッド | Ｉａｐのアザインドールインヒビター |
-
2008
- 2008-04-29 NZ NZ598890A patent/NZ598890A/xx not_active IP Right Cessation
- 2008-04-29 PE PE2008000757A patent/PE20090211A1/es not_active Application Discontinuation
- 2008-04-29 NZ NZ580226A patent/NZ580226A/xx not_active IP Right Cessation
- 2008-04-29 WO PCT/US2008/061891 patent/WO2008134679A1/en not_active Ceased
- 2008-04-29 BR BRPI0809867-0A patent/BRPI0809867A2/pt not_active IP Right Cessation
- 2008-04-29 US US12/598,027 patent/US8907092B2/en not_active Expired - Fee Related
- 2008-04-29 CL CL200801234A patent/CL2008001234A1/es unknown
- 2008-04-29 CA CA002683392A patent/CA2683392A1/en not_active Abandoned
- 2008-04-29 PE PE2012001805A patent/PE20130150A1/es not_active Application Discontinuation
- 2008-04-29 TW TW097115740A patent/TWI432212B/zh not_active IP Right Cessation
- 2008-04-29 EP EP08747109A patent/EP2148858A4/en not_active Withdrawn
- 2008-04-29 CN CN200880022901A patent/CN101687787A/zh active Pending
- 2008-04-29 AR ARP080101812A patent/AR066348A1/es not_active Application Discontinuation
- 2008-04-29 KR KR1020097024828A patent/KR20100024923A/ko not_active Abandoned
- 2008-04-29 MX MX2009011783A patent/MX2009011783A/es not_active Application Discontinuation
- 2008-04-29 RU RU2009144094/04A patent/RU2491276C2/ru not_active IP Right Cessation
- 2008-04-29 AU AU2008245447A patent/AU2008245447C1/en not_active Ceased
- 2008-04-29 JP JP2010506573A patent/JP5368428B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-06 ZA ZA2009/06946A patent/ZA200906946B/en unknown
- 2009-10-11 IL IL201379A patent/IL201379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001234A1 (es) | 2008-09-22 |
| TW200902067A (en) | 2009-01-16 |
| CN101687787A (zh) | 2010-03-31 |
| AU2008245447C1 (en) | 2014-11-20 |
| MX2009011783A (es) | 2009-12-04 |
| US8907092B2 (en) | 2014-12-09 |
| PE20090211A1 (es) | 2009-04-02 |
| WO2008134679A1 (en) | 2008-11-06 |
| ZA200906946B (en) | 2011-05-25 |
| RU2491276C2 (ru) | 2013-08-27 |
| US20110077265A1 (en) | 2011-03-31 |
| AU2008245447B2 (en) | 2014-01-23 |
| JP2010526079A (ja) | 2010-07-29 |
| EP2148858A4 (en) | 2011-01-26 |
| EP2148858A1 (en) | 2010-02-03 |
| TWI432212B (zh) | 2014-04-01 |
| CA2683392A1 (en) | 2008-11-06 |
| PE20130150A1 (es) | 2013-02-27 |
| NZ598890A (en) | 2013-10-25 |
| RU2009144094A (ru) | 2011-06-10 |
| IL201379A0 (en) | 2010-05-31 |
| JP5368428B2 (ja) | 2013-12-18 |
| AU2008245447A1 (en) | 2008-11-06 |
| BRPI0809867A2 (pt) | 2014-09-30 |
| NZ580226A (en) | 2012-11-30 |
| KR20100024923A (ko) | 2010-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| CY1123308T1 (el) | Αναστολεας ινωσης | |
| ES2606197T3 (es) | Moduladores pirrolidina de GPR40 | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR055774A1 (es) | Fenilacetamidas apropiadas como inhibidores de proteina quinasa | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| PE20091381A1 (es) | Inhibidores del virus de la hepatitis c | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| PE20130150A1 (es) | Inhibidores de las iap | |
| AR072488A1 (es) | Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas. | |
| CO6210724A2 (es) | Compuesto heterociclico y composicion farmaceutica del mismo | |
| AR065815A1 (es) | Compuestos de dihidroindazol en el tratamiento de trastornos del hierro | |
| MX2015005637A (es) | Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina. | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR087701A1 (es) | Derivados de pirazol con actividad inhibidora de sglt1 | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| AR069513A1 (es) | Derivados de amidas del acido 6,7-dihidro -5h-imidazo¿1,2-alfa]imidazol-3-carboxilico, y composiciones farmaceuticas que los contienen | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |